| |
PRODUCTS
Neuro
Biomed is focusing on the development of
a new class of neuroprotective agents
and an advanced drug delivery system for
the treatment of neurological disorders.
NB-3108:
a novel neuroprotective and neurogensis
agent
|
 |
Neuro
Biomed's first drug candidate in
clinical development is NB-3108, a
neuroprotective and neurogenesis agent.
NB-3108 is a novel neuroprotective agent
for acute treatment of stroke and
traumatic brain injury (TBI), as well as
for prophylactic treatment of
neurological damage associated with
coronary artery bypass graft (CABG).
|
The
initial targeted application of NB-3108
is for the treatment of stroke, which is
the third leading cause of death in the
US, Europe, and Japan. Over 500,000
stroke victims are reported every year
in the US alone. There are
approximate 500,000 ischemic incidents
resulting from traumatic brain injury
and open heart surgery, such as coronary
artery bypass graft (CABG).
|
 |
Current treatment is limited to thrombolytic therapy, which dissolves
the causative blood clots.
However, there is no approved compound
aimed at prevention or rescue of the
resultant neurological tissue damage.
The high mortality rates, and the
significantly higher disability
percentage resulting from such ischemic
events, are due mainly to this lack of
neuroprotective agents.
|
The
major challenge in development of
neuroprotective drugs, to date, has been
the prohibitive toxicity of compounds
directed at the early events which occur
upon an ischemic insult. The
second serious hurdle has been is that,
in order to achieve any effect, they had
to be administered within a very short
time frame after the insult; an
impossible feat under the current
medical procedures.
|
 |
The
neuroprotective capacity of NB-3108 was
validated in animal models of transient
cerebrovascular ischemia, where it was
shown to significantly minimize brain
damage as measured by infarct size.
In parallel studies, it was shown to
decrease the post-ischemia neurological
functional decline, even when
administered hours after the
insult. This has particular
significance in treatment of the
human affliction.
|
The wide
therapeutic window for administration
makes NB-3108 especially effective in
treatment of stroke and Traumatic Brain
Injury patients, with late hospital
admission.
The
preclinical safety results showing that
NB-3108 had no harmful side effects,
cardiac, respiratory, liver or other,
when administered to animals, even at
doses 100 times higher than the
effective dose.
NB-3108
exhibits a unique combination of
superior efficacy (in animal models of
stroke) combined with an excellent
safety profile, proven in pre-clinical
studies.
NanoBio Drug
Delivery System
Our patented
NanoBio Drug Delivery System is based on the
advanced development of the novel
nanostructure bio-electric membrane for drug
delivery and diagnostic applications.
-
NanoBio Membrane 's™
properties make it an ideal drug
delivery platform, with
high
efficiency/capacity of drug loading-up
to 97%
-
safe biodegradable product
-
Totally
needle-free delivery system for
injectable drug formulation.
-
Heat and
radiation stable for ease of gamma
radiation
-
Ensure
aseptic system with built-in nanoscale
membrane (50 nanometers) eliminating
particulates, bacteria, and endotoxin.
-
NanoBio
Membrane is suitable for most
injectable formulations
-
Nanoscale pore
size and Bio-electric charges can be
controlled to accommodate different
drug release pharmacokinetics (over
hours/days/weeks and months)
-
Bio-electric charges of the membrane
enable interface with
microelectronic processor for
precise programmable controlled
delivery
-
Self-regulating delivery system with
built-in microchip for ‘smart'
monitoring and diagnostic
applications.
For
further information, please contact our
Clinical Research Manager at research@neurobiomed.com
|